The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-5-(6-Chloro-5-fluoro-2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,3'-pyrrolidin]-1'-yl)-N-((6-((2-oxopyridin-1(2H)-yl)methyl)pyridin-3-yl)methyl)nicotinamide ID: ALA5285047
Max Phase: Preclinical
Molecular Formula: C29H24ClFN6O4
Molecular Weight: 575.00
Associated Items:
Names and Identifiers Canonical SMILES: O=C1Nc2ccc(Cl)c(F)c2[C@]2(CCN(c3cncc(C(=O)NCc4ccc(Cn5ccccc5=O)nc4)c3)C2)O1
Standard InChI: InChI=1S/C29H24ClFN6O4/c30-22-6-7-23-25(26(22)31)29(41-28(40)35-23)8-10-37(17-29)21-11-19(14-32-15-21)27(39)34-13-18-4-5-20(33-12-18)16-36-9-2-1-3-24(36)38/h1-7,9,11-12,14-15H,8,10,13,16-17H2,(H,34,39)(H,35,40)/t29-/m1/s1
Standard InChI Key: YTPBJIKJBISLLI-GDLZYMKVSA-N
Molfile:
RDKit 2D
41 46 0 0 0 0 0 0 0 0999 V2000
-3.8349 0.4080 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2471 1.1226 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8352 1.8344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0101 1.8344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5983 1.1244 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0064 0.4080 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.5976 2.5489 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7727 2.5489 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.3602 1.8344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5353 1.8344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1226 2.5488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6997 2.5481 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1124 1.8334 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7033 1.1217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1210 1.1170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1158 0.4073 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.9357 0.3212 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1072 -0.4852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3932 -0.8975 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7804 -0.3458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1075 -1.3099 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1075 -2.1349 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3932 -2.5474 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.6788 -2.1349 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6788 -1.3100 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.0356 -2.5474 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.8251 -2.5489 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5365 -2.1324 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5346 -1.3116 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8200 -0.8993 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8200 -0.0744 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
4.2491 -0.8991 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-1.7727 1.1201 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.2473 -0.3063 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8349 -1.0207 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.0099 -1.0210 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5993 -1.7336 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0119 -2.4482 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8327 -2.4498 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2491 -1.7382 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5974 -0.3065 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
6 5 2 0
1 6 1 0
4 7 1 0
7 8 1 0
8 9 1 0
9 10 1 0
11 10 2 0
12 11 1 0
13 12 2 0
14 13 1 0
15 14 2 0
10 15 1 0
16 14 1 0
16 17 1 0
17 18 1 0
19 18 1 1
19 20 1 0
20 16 1 0
19 21 1 0
22 21 2 0
23 22 1 0
24 23 1 0
25 24 1 0
19 25 1 0
24 26 2 0
22 27 1 0
27 28 2 0
28 29 1 0
29 30 2 0
21 30 1 0
30 31 1 0
29 32 1 0
9 33 2 0
1 34 1 0
34 35 1 0
36 35 1 0
37 36 1 0
38 37 2 0
39 38 1 0
40 39 2 0
35 40 1 0
36 41 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 575.00Molecular Weight (Monoisotopic): 574.1532AlogP: 4.08#Rotatable Bonds: 6Polar Surface Area: 118.45Molecular Species: NEUTRALHBA: 8HBD: 2#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: 12.49CX Basic pKa: 4.13CX LogP: 2.55CX LogD: 2.55Aromatic Rings: 4Heavy Atoms: 41QED Weighted: 0.36Np Likeness Score: -1.34
References 1. Abdel-Magid AF.. (2023) Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases., 14 (2.0): [PMID:36793429 ] [10.1021/acsmedchemlett.2c00526 ]